Hydrophilic next-generation linkers (TMALIN, Dolaflexin, sulfonyl-pyrimidine, PEG-containing)
Hydrophilic next-generation linkers have built-in sugars or polyethylene glycol that let ADCs carry more payload without clumping, and they resist efflux pumps.
Glucuronide-triggered linkers (cleaved by beta-glucuronidase), PEGylated linkers and sulfatase- or phosphatase-triggered designs increase hydrophilicity so drug-to-antibody ratios of eight are stable, reduce liver clearance and can yield released species that are poorer efflux-pump substrates. Several appear in next-generation topoisomerase-I and tubulin ADCs from Chinese and US developers.
Pages like this
not linked directly; found by shared links- TermT030 (belotecan derivative)
Shares Drug efflux pumps (ABC transporters), Sacituzumab tirumotecan, Antibody-drug conjugate (ADC).
- IdeaEfflux-agnostic therapy for mesenchymal TNBC
Shares Drug efflux pumps (ABC transporters), Sacituzumab tirumotecan, Antibody-drug conjugate (ADC).
- TermSMCC (thioether, non-cleavable)
- TermSulfo-SPDB (disulfide)
- TermMaleimidocaproyl (mc), non-cleavable
- TermAcid-labile hydrazone (AcBut)
- TermVal-Ala dipeptide
- TermCL2A